News articles about Orthofix International (NASDAQ:OFIX) have been trending somewhat positive this week, Accern Sentiment reports. Accern rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 44.9000586496684 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
A number of research firms recently weighed in on OFIX. BidaskClub lowered shares of Orthofix International from a “hold” rating to a “sell” rating in a research report on Thursday, January 18th. TheStreet lowered shares of Orthofix International from a “b” rating to a “c+” rating in a report on Tuesday, October 31st. BTIG Research set a $56.00 target price on shares of Orthofix International and gave the company a “buy” rating in a report on Monday, October 30th. Finally, Zacks Investment Research upgraded shares of Orthofix International from a “hold” rating to a “buy” rating and set a $60.00 target price on the stock in a report on Thursday, November 2nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $54.42.
Orthofix International (OFIX) traded down $0.48 during trading hours on Friday, reaching $57.19. 113,394 shares of the company’s stock traded hands, compared to its average volume of 163,987. The firm has a market cap of $1,047.19 and a price-to-earnings ratio of 817.12. Orthofix International has a 12 month low of $33.90 and a 12 month high of $58.22.
Orthofix International (NASDAQ:OFIX) last posted its earnings results on Monday, October 30th. The medical device company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.01. The company had revenue of $105.30 million for the quarter, compared to analyst estimates of $100.67 million. Orthofix International had a net margin of 0.33% and a return on equity of 10.26%. Orthofix International’s revenue was up 6.9% on a year-over-year basis. During the same period in the previous year, the business posted $0.36 EPS. analysts forecast that Orthofix International will post 1.61 EPS for the current fiscal year.
In other news, Director Luke T. Faulstick sold 4,800 shares of the business’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $51.22, for a total value of $245,856.00. Following the sale, the director now directly owns 7,729 shares of the company’s stock, valued at approximately $395,879.38. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Bradley V. Niemann sold 5,547 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $52.08, for a total transaction of $288,887.76. Following the completion of the sale, the insider now directly owns 34,631 shares in the company, valued at $1,803,582.48. The disclosure for this sale can be found here. Insiders sold a total of 15,347 shares of company stock worth $802,144 over the last three months. Insiders own 5.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/02/orthofix-international-ofix-given-coverage-optimism-rating-of-0-19.html.
About Orthofix International
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.